In summary, this study indicates that genetically predicted long-term rises in endogenous EPO levels do not increase cardiovascular risk, with upper limits of 1.07, 1.15, and 1.07 for CAD, MI, and stroke, respectively, given a clinically relevant 2.2 unit rise in endogenous EPO levels. Here, EPO is linked to myocardial infarction.